NCT05930210招募中3 期
A Randomized, Double-Blind, Vehicle-controlled, Parallel, Phase III Study to Evaluate Efficacy and Safety of ENERGI-F703 GEL in Subjects With Diabetic Foot Ulcers
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 230
- 试验地点
- 24
- 主要终点
- The ulcer complete closure rate
研究概览
简要总结
This Phase 3 study is a randomized, double-blind, vehicle-controlled, multiple-center, parallel study to evaluate efficacy and safety of ENERGI-F703 GEL compared with vehicle control in subjects with Wagner Grade 1 to Grade 2 diabetic foot ulcers. Baseline target ulcer size (<16 cm2 vs ≥16 cm2 ) will be included as a stratification factor. Subjects will be randomized 1:1 to receive ENERGI-F703 GEL or vehicle control using an interactive web response system for randomization to automatically assign a unique subject randomization number. Total duration of the study will be up to 31 weeks including Screening visit (approximately 2 to 3 weeks), double-blind dosing/observation phase (16 weeks), and a safety follow-up of 12 weeks after the last administration of study treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject must be at least 18 years old.
- •Subject must have diagnosed with diabetes mellitus (DM), eg, currently under DM medication treatment or subjects with naïve DM with duplicated hemoglobin A1c over 6.5% and fasting plasma glucose over 126 mg/dL measured at least 1 week apart before screening.
- •Subject must have at least 1 cutaneous ulcer on the foot and not healing for at least 4 weeks. The largest diabetic foot ulcer will be selected as target ulcer. If 2 or more ulcers have the largest size, the one with worst grade will be selected. If 2 or more ulcers have the largest size and grade, the one with longest duration will be selected.
- •The target ulcer is classified as Grade 1 to Grade 2 ulcer according to Wagner Grading System and with ulcer size of 1.5 cm2 to 25 cm
- •Diabetic foot ulcers should be free of any necrosis or infection
- •Subject has signed the written informed consent form
- •Male subjects must be surgically sterile or commit to the use of a reliable method of birth control (must agree to use double-barrier contraception in the event of sexual activity) or be practicing abstinence for the duration of the study and for 30 days after study treatment administration.
- •Female subjects are eligible only if all of the following apply:
- •Not pregnant with a negative serum pregnancy test at Screening visit and negative urine pregnancy test within 24 hours before randomization (test not required for females of non-childbearing potential, defined as surgically sterile [eg, hysterectomy or bilateral oophorectomy] or postmenopausal [amenorrheic for at least 1 year])
- •Not lactating
- •Not planning to become pregnant during the study
- •If of childbearing potential, commits to the use of a highly effective method of contraception for the duration of the study and at least 30 days after study treatment administration.
排除标准
- •History or evidence of osteomyelitis as confirmed by the investigator. An x-ray/pathology assessment of debridement or a probe-to-bone (PTB) test will be used to determine presence of osteomyelitis. However, participants who have a history or evidence of osteomyelitis in other parts of their body are eligible to participate in the study. If the medical history of osteomyelitis was cured by antibiotic therapy, surgery or amputation for more than 1 year, and no recurrence, no finding to the current leg and foot after testing, the participant can be enrolled
- •With target ulcer size decreased by at least 30% after at least 2 weeks of standard of care-only period between screening and randomization
- •Subjects with highly exudated wounds which require dressing changes more than 3 times a day may be enrolled, but heavily exudated wounds should not be selected as target ulcers
- •With poor nutritional status (serum albumin <2g/dL or prealbumin <10 mg/dL), poor diabetic control (hemoglobin A1c >12%), a leukocyte counts <2,000/mm3, abnormal liver function (aspartate aminotransferase, alanine aminotransferase >3 x upper limit of normal range) within 21 days before Randomization visit
- •Requiring treatment with systemic corticosteroids, immunosuppressive or chemotherapeutic agents
- •With known or suspected hypersensitivity to any ingredients of study product and vehicle
- •With coronary heart disease with myocardial infarction, coronary artery bypass graft, or percutaneous transluminal coronary angioplasty within 3 months prior to study (patients who have undergone peripheral angioplasty should be excluded unless the surgery was performed at least 30 days prior to screening)
- •Known or suspected history of drug abuse or a recent history of alcohol abuse (regularly drinks >4 units of alcohol per day: 1 unit = 8 oz. beer, 3 oz. wine, or 1 oz. spirits) within 6 months prior to screening (within 6 months prior to screening includes both drug abuse and alcohol abuse)
- •History or positive test results for HIV
- •Malignancy in the last 2 years, with the exception of non-metastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix
- •Ankle brachial index <0.8 or >1.4
- •Enrollment in any investigational drug trial within 4 weeks before entering this study
- •With any condition judged by the investigator that entering the trial may be detrimental to the subject -
研究组 & 干预措施
ENERGI-F703 GEL
Experimental
ENERGI-F703, topical application, 2 times daily for 16 weeks
干预措施: ENERGI-F703 GEL (Drug)
ENERGI-F703 matched vehicle
Placebo Comparator
ENERGI-F703 matched vehicle, topical application, 2 times daily for 16 weeks
干预措施: ENERGI-F703 matched vehicle (Drug)
结局指标
主要结局
The ulcer complete closure rate
时间窗: Weeks 16
Proportion of subjects with a recording of complete ulcer closure at Week 16 (the end of the treatment period) as assessed by the investigator, where such closure is subsequently confirmed at 2 consecutive study visits over a 2-week period (ie, by Week 18). A complete ulcer closure is defined as 100% skin re epithelialization without drainage or dressing requirements.
次要结局
- The time to ulcer closure(Weeks 4, 6, 8, 10, 12, 14, and 16)
- The frequency and severity of adverse events(Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, and 28)
- The proportion of subjects with complete ulcer closure(Weeks 4, 6, 8, 10, 12, 14, and 16)
研究者
研究点 (24)
Loading locations...
相似试验
撤回
3 期
Efficacy and Safety Study of MSRD-100 in Subjects With Atopic Dermatitis >=3 Months of Age and OlderAtopic DermatitisNCT02677610Merz North America, Inc.
撤回
3 期
Efficacy and Safety Study of MSRD-100 in Subjects With Atopic Dermatitis >=3 Months of Age and OlderAtopic DermatitisNCT02677636Merz North America, Inc.
已完成
3 期
A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)Molluscum ContagiosumNCT03927716Novan, Inc.352
已完成
3 期
A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MCMolluscum ContagiosumNCT03927703Novan, Inc.355
已完成
3 期
A Phase 3 Molluscum Contagiosum Efficacy and Safety StudyMolluscum ContagiosumNCT04535531Novan, Inc.891